1. X
  2. Ben Derman
Log inSign up
Ben Derman
3,601 posts
Image
user avatar
Ben Derman
@bdermanmd
Asst Professor at UChicago, interim director myeloma program. I tweet about: Myeloma & MRD. linktr.ee/bderman
Chicago, IL
Joined June 2017
390
Following
4,497
Followers
RepliesRepliesMediaMedia

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up
  • user avatar
    Ben Derman
    @bdermanmd
    Nov 4, 2021
    The @UChicago campus is simply stunning right now! Reminded of this beautiful short story by O. Henry “The Last Leaf” about the sacrifices people make for the ones they love. americanenglish.state.gov/files/ae/resou…
    Image
    Image
    Image
    Image
  • user avatar
    Ben Derman
    @bdermanmd
    Jul 5, 2025
    In-vivo CAR Ts for myeloma are going to come fast and furious. These products are engineering marvels. ESO-T01 (EsoBiotec) is an anti-BCMA in-vivo CAR T that: 1) Delivers the CAR transgene to endogenous T-cells, reprogramming them to CAR T cells in situ 2) Overexpress CD47 to
    Image
    18K018K
  • user avatar
    Ben Derman
    @bdermanmd
    May 10, 2025
    Cilta-cel associated Parkinsonism remains a challenge. Instead of going right to high dose Cy which can be toxic to circulating CAR T cells, we opted to try intrathecal chemotherapy in 5 consecutive cases. 4/5 pts had a response and 3 complete resolution! IT chemo seemed to be
    Image
    18K018K
  • user avatar
    Ben Derman
    @bdermanmd
    Oct 9, 2024
    What happens when patients with myeloma and sustained MRD negativity choose to discontinue maintenance? We sought to answer this question in our study MRD2STOP, out now in @BloodCancerJnl nature.com/articles/s4140…
    Image
    26K026K
  • user avatar
    Ben Derman
    @bdermanmd
    Mar 2, 2022
    What a difference 4 cycles of quadruplet induction can make in myeloma. Before (left) and after (right). Brings me so much joy! Next stop: MRD-negativity please. #mmsm
    Image
  • user avatar
    Ben Derman
    @bdermanmd
    Jul 1, 2020
    A bit of personal news: I have joined the faculty @UCCancerCenter as part of the plasma cell disorders program. I am incredibly grateful to the many influential mentors who have guided me along the way & I will continue working toward making the lives of myeloma pts better!
  • user avatar
    Ben Derman
    @bdermanmd
    Sep 7, 2022
    Are we curing myeloma? I think we are in some cases. Maybe this patient is on their way! Off therapy for 2 years now and MRD negative by NGS since then! What do you think? #mmMRD #mmsm
    Image
  • user avatar
    Ben Derman
    @bdermanmd
    Nov 20, 2023
    In anticipation of #ASH23, I have scoured the conference abstracts. Here's what I think are 10 important abstracts on myeloma! A little bit of everything - newly diagnosed myeloma, CAR T/BsAb, and diganostics! Let’s go! #mmsm
    37K037K
  • user avatar
    Ben Derman
    @bdermanmd
    May 5, 2022
    What does a 'cure' mean in multiple myeloma? Is it even possible? In this review, we first try to define a cure and then provide the evidence for why some patients may actually reach this milestone. First: our definition (see below). authors.elsevier.com/a/1f0qL,yeo3ud…
    We define cure in myeloma as (1) having no evidence of disease, (2) no longer being on therapy, (3) having limited comorbidities from the disease, and (4) having mortality similar to age-matched pop.
  • user avatar
    Ben Derman
    @bdermanmd
    May 30, 2025
    🧵 Top 10 ASCO 2025 Myeloma Abstracts – A Thread Here’s what stands out from this year’s abstracts - more to come after presentations! Updates in bispecifics, MRD-guided therapy, CAR-T, and trispecifics. 👇
    12K012K
  • user avatar
    Ben Derman
    @bdermanmd
    Feb 11, 2021
    A liquid biopsy for myeloma may be closer than we think! Excited to share our work on MRD in the peripheral blood using mass spectrometry! We found mass spec may exceed the sensitivity of bone marrow based methods w/superior prognostication #mmsm #mmMRD bit.ly/MRDmyeloma
  • user avatar
    Ben Derman
    @bdermanmd
    Oct 21, 2024
    What do you do when you need effective bridging therapy for pts w/myeloma waiting for CAR T-cell manufacture? Our awesome resident Dr. Marcus Marable @UChicagoMed reports on 'TurboCy' as effective bridging therapy! Delivered in 24 hours w/no central line!
    Image
    onlinelibrary.wiley.com
    Rapid high‐dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma
    Patients with relapsed/refractory multiple myeloma proceeding with chimeric antigen receptor (CAR) T-cell therapy or bispecific antibodies (BsAb) may need bridging therapy to realize their benefits....
    13K013K
  • user avatar
    Ben Derman
    @bdermanmd
    Dec 5, 2022
    So many excellent #ASH22 abstracts to choose from. Sharing my thoughts on 11 important works, with more to come as we get closer to the meeting! In order of abstract number (not merit)...let's go! #mmsm
  • user avatar
    Ben Derman
    @bdermanmd
    Jun 2, 2023
    Are you ready for an #ASCO23 myeloma megathread? Here are 10 important abstracts to tune into to learn more (esp. with so little data in the abstract!). Let's go! #mmsm
    26K026K
Advertisement
Advertisement